TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3303983
Drug: Steam inhalation
Normalized name: Leader Hot Steam Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steam inhalation (two 20-minute sessions of inhaling saturated, hot air at 42-44 degrees C)
Study: 29936590
Drug: Epinephrine (0.2-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (0.2-0.4 μg/kg/min)
Study: 29936590
Drug: Dopamine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (10-20 μg/kg/min)
Study: 25196061
Drug: 90 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 μg PEG‐IFNα‐2a weekly
Study: 25196061
Drug: 135 μg
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 135 μg PEG‐IFNα‐2a weekly
Study: 25196061
Drug: PEG‐IFNα‐2a treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFNα‐2a treatment with HCV RNA negativation at 4 weeks
Study: 25196061
Drug: PEG‐IFNα‐2a treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFNα‐2a treatment with HCV RNA positivity at 24 weeks
Study: 25196061
Drug: Treatment discontinuation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment discontinuation due to adverse events
Study: 29420335
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (ICT)
Study: 22843377
Drug: Primary alternating
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary alternating CRT or concurrent CRT (non-ICT)
Study: 20016011
Drug: Iron-fortified milk
Normalized name: iron succinyl milk protein complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified milk (FM); Daily portion contained 5.28 mg Fe (ferrous gluconate) and 48 mg sodium ascorbate
Study: 17573492
Drug: Good compliance
Normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Good compliance to CPAP treatment (n = 20)
Study: 17573492
Drug: Poor compliance
Normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Poor compliance to CPAP treatment (n = 19)
Study: 17573492
Drug: Refusal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refusal of CPAP treatment (n = 14)
Study: 16213352
Drug: Low-dose histidine-tryptophan-ketoglutarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose histidine-tryptophan-ketoglutarate (HTK) solution
Study: 9557112
Drug: Immunohistochemical analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemical analysis for oestrogen and progesterone receptors
Study: 3920695
Drug: Desipramine (DMI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (DMI, 150 mg/day for 28 days)
Study: 3920695
Drug: Amitriptyline (AT,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (AT, dosage not specified for 28 days)
Study: 3069519
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine (10-40 mg/day)
Study: 3069519
Drug: Paracetamol (1000-4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1000-4000 mg/day)/codeine (60-240 mg/day)
Study: 30476217
Drug: Regular diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular diet mixed with a commercial synbiotic product at 1.0 g/kg (1.0X)
Study: 30476217
Drug: Regular diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular diet mixed with a commercial synbiotic product at 0.5 g/kg (0.5X)
Study: 23437909
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose SST (250 μg bolus + continuous infusion of 250 μg/h)
Study: 23437909
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose SST (500 μg bolus + continuous infusion of 250 μg/h)
Study: 23437909
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose SST (250 μg bolus + continuous infusion of 500 μg/h)
Study: 23437909
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo saline injection + placebo infusion)
Study: 19894302
Drug: Cereton 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereton 1000 mg intramuscular for 15 days
Study: 9050731
Drug: Diagnostic laparoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic laparoscopy without treatment
Study: 9050731
Drug: Danazol 800
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 800 mg/day for 3 months after diagnostic laparoscopy
Study: 3943883
Drug: Alpha-methyldopa (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-methyldopa (500 mg oral dose)
Study: 27470026
Drug: Atazanavir 200
Normalized name: atazanavir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 200 mg and ritonavir 100 mg (low dose)
Study: 27470026
Drug: Atazanavir 300
Normalized name: atazanavir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 300 mg and ritonavir 100 mg (standard dose)
Study: 18953082
Drug: lisinopril/hydrochlorothiazide with
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril/hydrochlorothiazide with ibuprofen
Study: 18953082
Drug: lisinopril/hydrochlorothiazide with
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril/hydrochlorothiazide with piroxicam
Study: 18953082
Drug: lisinopril/hydrochlorothiazide with
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril/hydrochlorothiazide with acetaminophen
Study: 18953082
Drug: lisinopril/hydrochlorothiazide with
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril/hydrochlorothiazide with ibuprofen or piroxicam (second exposition)
Study: 18953082
Drug: amlodipine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine with ibuprofen or piroxicam
Study: 15987289
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day
Study: 15987289
Drug: 100 mg/week
Normalized name: selinexor 100 mg/week (20 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/week
Study: 15987289
Drug: 400 mg/week
Normalized name: tovorafenib 400 mg/week (100 mg x 4) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/week
Study: 8522380
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ceftazidime i.v. t.d.s.
Study: 8522380
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg ceftazidime i.v. t.d.s.
Study: 6111438
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of beta-receptor blocker and diuretic (10 mg pindolol and 5 mg clopamide daily)
Study: 6111438
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of beta-receptor blocker, diuretic and sodium-preserving diuretic (10 mg timolol, 25 mg hydrochlorothiazide and 2.5 mg amiloride)
Study: 28939629
Drug: Prolongation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolongation of adalimumab dosing interval to once every 3 weeks
Study: 28939629
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of adalimumab dosing interval every other week
Study: 26201083
Drug: Adolescent-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescent-focused therapy
Study: 22546131
Drug: Liposome bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome bupivacaine (LB) 66, 199, or 266 mg
Study: 22546131
Drug: bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupivacaine HCl 75 mg
Study: 20133204
Drug: Pulsed high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed high-dose dexamethasone
Study: 20133204
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral prednisolone
Study: 17397425
Drug: Multifactorial falls
Normalized name: Halls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial falls intervention (two in-home visits, recommendations, referrals, 11 monthly calls, balance exercise plan)
Study: 15736248
Drug: Trapidil 200
Normalized name: trapidil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trapidil 200 mg t.i.d. for 6 months
Study: 11896096
Drug: Fluorouracil (5-FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (5-FU) chemotherapy at doses of 370 to 450 mg/m² for 5 consecutive days
Study: 11896096
Drug: Fluorouracil (5-FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (5-FU) chemotherapy
Study: 7659440
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (KET) 60 mg before induction (PRE group)
Study: 7659440
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline followed by intravenous ketorolac (KET) 60 mg (POST group)
Study: 7659440
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (KET) 60 mg (PRE group)
Study: 2683424
Drug: HDL-rich Cohn-IV-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDL-rich Cohn-IV-1 fractions infusion (100 ml every 2 weeks)
Study: 2683424
Drug: Cholestyramine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine and a choleretic drug (permanent medication)
Study: 25046539
Drug: Isoproterenol (ISO:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol (ISO: 0.05 μg/kg per minute)
Study: 21834938
Drug: PP 1420
Normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PP 1420 (2, 4, and 8 mg)
Study: 20507969
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (IMT) - 4 weeks, 30 breaths twice daily at approximately 50% of maximum inspiratory pressure (MIP)
Study: 20507969
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment - 4 weeks, 60 breaths once daily at approximately 15% of MIP
Study: 18699898
Drug: Ephedrine 70
Normalized name: guaifenesin-pseudoephedrine 700 mg-80 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 70 microg.kg(‐1) administered at 4 min before rocuronium
Study: 18699898
Drug: Saline administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administered at 4 min before rocuronium (Control)
Study: 18699898
Drug: Ephedrine 70
Normalized name: guaifenesin-pseudoephedrine 700 mg-80 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 70 microg.kg(‐1) administered at 30 s before rocuronium (Late)
Study: 9129896
Drug: Digoxin 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 1.25 mg
Study: 1901187
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms vaccine
Study: 9251847
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms vaccine
Study: 1901187
Drug: 150 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 micrograms vaccine
Study: 7092002
Drug: Tetracycline, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline, 500 mg by mouth every 6 hours for 1 week
Study: 30798020
Drug: Ambulatory assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory assessment methods for treatment adherence and substance use data collection
Study: 30798020
Drug: Eligibility criteria
Normalized name: DIMETHICONE 1 g in 100 mL TOPICAL GEL [JAFRA Fruteria So Citrico]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligibility criteria verification, treatment adherence monitoring, and remote assessment of substance use and biomarkers
Study: 24560581
Drug: Alcohol (breath
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (breath alcohol concentration of .6 g/kg)
Study: 22038192
Drug: Phonophoresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonophoresis with non-steroid anti-inflammatory drug (PNSAI)
Study: 19106767
Drug: Guanfacine extended
Normalized name: Guanfacine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine extended release (GXR) 1-4 mg doses
Study: 9541371
Drug: Oral feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feedback (University 1)
Study: 9541371
Drug: Oral feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feedback (University 2)
Study: 22617128
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid (ZOL) 4 mg every 3 weeks for 1 year
Study: 17805038
Drug: Erwinia asparaginase
Normalized name: Erwinia asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erwinia asparaginase (ASP) substituted at the same dose and schedule due to allergic reaction to E. coli ASP
Study: 17805038
Drug: Intramuscular E.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular E. coli ASP (6000 U/m2x6) followed by intensive weekly intramuscular E. coli ASP (25,000 U/m2/wkx24)
Study: 9735610
Drug: Systemic-behavioral family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic-behavioral family therapy
Study: 30580203
Drug: Manual-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual-only treatment program for caffeine cessation and reduction over a period of 6 weeks; no counseling or additional support.
Study: 30580203
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment group (manual-only treatment).
Study: 30580203
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment group (treatment delayed by 7 weeks).
Study: 26115748
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine triphosphate (ATP) administered after successful PVI to reveal dormant conduction (DC) sites.
Study: 21997315
Drug: Rimonabant (10-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant (10-week treatment)
Study: 23389382
Drug: Placebo (10-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10-week treatment)
Study: 16959685
Drug: Combined systemic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined systemic and local Pycnogenol treatment
Study: 16959685
Drug: Oral Pycnogenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Pycnogenol only
Study: 20943066
Drug: Medications only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications only (control group)
Study: 14976608
Drug: Fosmidomycin-clindamycin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosmidomycin-clindamycin (30 and 5 mg/kg body weight every 12 h for 5 days)
Study: 14976608
Drug: Fosmidomycin alone
Normalized name: Fosmidomycin
DrugBank: Fosmidomycin (DB02948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosmidomycin alone (30 mg/kg body weight every 12 h for 5 days)
Study: 14976608
Drug: Clindamycin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin alone (5 mg/kg body weight every 12 h for 5 days)
Study: 9469525
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 mg subcutaneous before surgery and 30 ml saline infiltrated into the wound at skin incision)
Study: 9469525
Drug: Saline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (1 ml into an arm before surgery) and Morphine (10 mg in 30 ml saline into the wound at skin incision)
Study: 9469525
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of i.v. morphine
Study: 2907519
Drug: Propranolol (40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40, 80 mg twice daily)
Study: 2907519
Drug: Ketanserin (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20, 40 mg twice daily)
Study: 2907519
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Propranolol added to Ketanserin)
Study: 2907519
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Ketanserin added to Propranolol)
Study: 25450868
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of sclerosant through an occluding balloon catheter (OB technique)
Study: 25450868
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of sclerosant through a diagnostic catheter (free catheter technique)
Study: 21692281
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) combined with psychological interference (combined therapy group)
Study: 21692281
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy group (EA + psychotherapy)
Study: 11979157
Drug: Extensive multidisciplinary
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extensive multidisciplinary treatment program
Study: 11979157
Drug: Light multidisciplinary
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light multidisciplinary treatment program
Study: 16310718
Drug: Treatment-as-usual initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual initiated by a general practitioner
Study: 15110919
Drug: Newborns with
Normalized name: Vital E- Newborn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newborns with parental atopy and elevated cord IgE (> or = 0.5 kU/l)
Study: 9311710
Drug: Neoral (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral (10 mg/kg/day)
Study: 9311710
Drug: Sandimmune (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmune (10 mg/kg/day)
Study: 8141713
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (SK) and subcutaneous heparin (n = 9796)
Study: 8141713
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (SK) and intravenous heparin (n = 10,377)
Study: 8141713
Drug: Accelerated tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated tissue plasminogen activator (t‐PA) and intravenous heparin (n = 10,344)
Study: 27084867
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera gel along with physiotherapy
Study: 27084867
Drug: Antioxidant capsules
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant capsules along with physiotherapy
Study: 15946410
Drug: GLU+FRUC (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLU+FRUC (1.2 g/min glucose + 1.2 g/min fructose)
Study: 15946410
Drug: GLU (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLU (1.2 g/min glucose)
Study: 12680333
Drug: Intrameatal application
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrameatal application of low dosage alprostadil (PGE1) cream (300 mcg)
Study: 10525926
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (therapy only in case of occurrence of atrial fibrillation)
Study: 20626055
Drug: External Qigong
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External Qigong Treatment (EQT)
Study: 17405567
Drug: New drug-elution
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drug-elution stents
Study: 10381908
Drug: rNV VLPs
Normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
Approvals — FDA: no, EMA: no, PMDA: no
Description: rNV VLPs (250 micrograms) administered orally on days 1 and 21
Study: 10381908
Drug: rNV VLPs
Normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
Approvals — FDA: no, EMA: no, PMDA: no
Description: rNV VLPs (250 micrograms) administered orally
Study: 8917873
Drug: Hospital dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital dosing
Study: 6123675
Drug: Metkephamid acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metkephamid acetate 70 mg
Study: 6123675
Drug: Pethidine hydrochloride
Normalized name: Pethidine hydrochloride
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine hydrochloride 100 mg
Study: 28694884
Drug: Local steroid
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local steroid injections
Study: 28694884
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (exercise + local steroid injections)
Study: 25565079
Drug: Box-Cox transformation
Normalized name: ALLERGENIC EXTRACT, BOX ELDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Box-Cox transformation method for treatment effect estimation
Study: 20872043
Drug: Sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib malate at a daily dose of 37.5 mg until progression or unacceptable toxicity
Study: 20872043
Drug: Sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib malate at a daily dose of 37.5 mg
Study: 10945486
Drug: Irinotecan single-agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan single-agent after 5-FU failure
Study: 9294406
Drug: Dysport (muscle-relaxant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysport (muscle-relaxant doses)
Study: 31516033
Drug: D/C/F/TAF (800/150/200/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: D/C/F/TAF (800/150/200/10 mg)
Study: 30899941
Drug: Twin-block appliance
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twin-block appliance treatment in experimental group (21 patients)
Study: 21182783
Drug: Levosimendan 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan 0.2 μg·kg(‐1)·min(‐1)
Study: 21182783
Drug: Dobutamine 5
Normalized name: dobutamine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine 5 μg·kg(‐1)·min(‐1) (control)